BioSpace News Archive

NLS Pharmaceutics Ltd. announced that it has submitted the Company’s plan, on time, to regain compliance with Nasdaq Listing Rule 5550.

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has obtained prequalification certification from the World Health Organization for its typhoid conjugate vaccine, ‘SKYTyphoid®'.

Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer’s disease (AD).

Vir Biotechnology, Inc. announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston.

BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.

Biofrontera Inc. announced that it has closed on a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors as of February 22, 2024.

Quest Diagnostics Incorporated (NYSE: DGX) announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company’s strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m. Eastern Time.

Celltrion today presented positive two-year results from the extended LIBERTY studies (LIBERTY-CD1 and LIBERTY-UC2) in patients with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).

Biogen Inc. announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® for the treatment of adults with amyotrophic lateral sclerosis, associated with a mutation in the superoxide dismutase 1 gene.

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Reblozyl® (luspatercept) as a treatment for adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).